Jazz Pharmaceuticals receives NICE recommendation for the reimbursement of Epidyolex® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex in England
Retrieved on:
Tuesday, January 31, 2023
Newton, Dravet syndrome, Tuberous sclerosis, TSA, Heart, Jazz Pharmaceuticals, EMA, GW, Strategic planning, Medicines and Healthcare products Regulatory Agency, Seizure, NHS, Medicine, Skin, TSC, Epilepsy, Lennox–Gastaut syndrome, Cannabidiol, NICE, Wales, GW Pharmaceuticals, Brain, MHRA, Patient, National Institute for Health and Care Excellence, Ann Mercy Hunt, Clobazam, Healthcare Improvement Scotland, European Medicines Agency, Pharmaceutical industry
TSC can be diagnosed in infancy but many children are not diagnosed until later in childhood when their seizures begin and other symptoms appear.
Key Points:
- TSC can be diagnosed in infancy but many children are not diagnosed until later in childhood when their seizures begin and other symptoms appear.
- [4] It is estimated that between 3,700 and 11,000 people in the UK live with TSC.
- TSC is a very difficult to manage condition, with common issues including epilepsy in eight out of ten people.
- Please note that, in relation to this Jazz media announcement, no honorarium was provided to the Tuberous Sclerosis Association.